+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Burkholderia Pseudomallei Infection Drug"

Burkholderia Pseudomallei Infections Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Burkholderia Pseudomallei Infections Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • June 2023
  • 74 Pages
  • Global
From
Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 41 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Burkholderia Pseudomallei Infection Drug market is a subset of the Infectious Diseases Drugs market. It is focused on the development of drugs to treat infections caused by the Burkholderia pseudomallei bacteria. These infections can cause a range of symptoms, including fever, chills, and muscle aches, and can be fatal if left untreated. Treatment typically involves antibiotics, and the market is focused on the development of new and improved antibiotics to treat these infections. The market is highly competitive, with a number of companies developing new drugs to treat Burkholderia pseudomallei infections. These companies include Merck, Pfizer, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more